Nurix Therapeutics ( (NRIX) ) has issued an update.
On March 11, 2025, Nurix Therapeutics appointed Dr. Roy D. Baynes to its board of directors and as a member of the Clinical and Commercialization Committee. Dr. Baynes, who has extensive experience in hematology and oncology, will contribute to advancing Nurix’s pipeline across oncology and autoimmune indications. His appointment is expected to enhance the company’s clinical development and commercialization efforts, particularly in the face of growing resistance to BTK inhibitors.
More about Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on the discovery, development, and commercialization of targeted protein degradation medicines. The company is advancing a pipeline that includes degraders of Bruton’s tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with collaborations with major pharmaceutical companies like Gilead Sciences, Sanofi, and Pfizer.
YTD Price Performance: -25.47%
Average Trading Volume: 748,828
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.05B
Find detailed analytics on NRIX stock on TipRanks’ Stock Analysis page.